Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An update from Veritas In Silico Inc. ( (JP:130A) ) is now available.
Veritas In Silico Inc. and Dexerials Corporation have announced a joint technology development initiative to create high-speed and accurate spectroscopic RNA structure measurement methods. This collaboration aims to enhance RNA structural analysis, complementing existing techniques and potentially benefiting RNA manufacturing processes. The development is expected to strengthen Veritas In Silico’s ibVIS® platform and contribute to scientific advancements, with plans for future commercialization.
More about Veritas In Silico Inc.
Veritas In Silico Inc. operates in the biotechnology industry, focusing on RNA structure analysis and drug discovery. The company is known for its proprietary ibVIS® platform, which is used for discovering mRNA-targeted small molecule drugs and nucleic acid therapeutics. Veritas In Silico collaborates with pharmaceutical companies and is working on creating a pipeline of nucleic acid drugs.
Average Trading Volume: 107,222
Technical Sentiment Signal: Sell
Current Market Cap: Yen3.59B
For detailed information about 130A stock, go to TipRanks’ Stock Analysis page.